BLU GIST
21 Dec 2020
Trial Summary
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs
Acronym:
VOYAGER
ACTRN/NCT /ethics:
NCT03465722
Scientific title:
Study of Avapritinib (BLU-285) vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Sponsor / Cooperative group:
Blueprint Medicines Corporation
Trial & Patient Characteristics
| Cancer Type | Stomach & Oesophageal |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2021-03-26 |
| Anticipated End Date | 2023-04-01 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Amitesh Roy |
| Recruitment Status | Recruitment on Hold |